Topoisomerase Ii as a cellular receptor of various antineoplastic drugs
Szmigiero, L.
Postepy Biochemii 34(3): 147-152
1988
ISSN/ISBN: 0032-5422 PMID: 2855749 Document Number: 313976
Document emailed within 1 workday
Related Documents
Le Guern, M. 1987: DNA-topoisomerase II: Cellular targets of antineoplastic agents Pathologie-Biologie 35(4): 343-345Wrześniok, D.; Buszman, E.; Matusiński, B. 2003: Drugs ototoxicity. Part II. Loop diuretics, nonsteroidal anti-inflammatory drugs, antineoplastic and antimalarial drugs Wiadomosci Lekarskie 56(7-8): 369-374
Trissel, L.A.; Parks, N.P.; Santiago, N.M. 1991: Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection American Journal of Hospital Pharmacy 48(10): 2186-2189
Arakawa, Y. 2015: DNA topoisomerase I--targeting drugs Nihon Rinsho. Japanese Journal of Clinical Medicine 73(Suppl 2): 174-177
Gutzler, F. 1996: New drugs. Topoisomerase inhibitors Zentralblatt für Gynakologie 118(10): 579
Morjani, H.; Riou, J.F.; Nabiev, I.; Lavelle, F.; Manfait, M. 1993: Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy Cancer Research 53(20): 4784-4790
De Isabella, P.; Capranico, G.; Palumbo, M.; Sissi, C.; Krapcho, A.P.; Zunino, F. 1993: Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects Molecular Pharmacology 43(5): 715-721
Coleman, L.W.; Bronstein, I.B.; Holden, J.A. 2001: Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas Anticancer Research 21(2a): 1167-1172
Herzog, C.E.; Holmes, K.A.; Tuschong, L.M.; Ganapathi, R.; Zwelling, L.A. 1998: Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha Cancer Research 58(23): 5298-5300
Malek, T.R.; Schmidt, J.A.; Shevach, E.M. 1985: The murine IL 2 receptor. III. Cellular requirements for the induction of IL 2 receptor expression on T cell subpopulations Journal of Immunology 134(4): 2405-2413
Meikle, I.; Cummings, J.; Macpherson, J.S.; Smyth, J.F. 1995: Identification of anthracenyl-dipeptide conjugates as novel topoisomerase i and Ii inhibitors and their evaluation as potential anticancer drugs Anti-Cancer Drug Design 10(7): 515-527
Newman, S.L.; Mikus, L.K.; Tucci, M.A. 1991: Differential requirements for cellular cytoskeleton in human macrophage complement receptor- and Fc receptor-mediated phagocytosis Journal of Immunology 146(3): 967-974
Williams, S.F.; Schilsky, R.L. 2000: Antineoplastic drugs administered during pregnancy Seminars in Oncology 27(6): 618-622
Ng, L.M.; Jaffe, N. 1970: Possible hazards of handling antineoplastic drugs Pediatrics 46(4): 648-649
Williams, S.F.; Schilsky, R.L. 2000: Antineoplastic drugs administered during pregnancy Seminars in Oncology 27(6): 618-622
Neiger, R. 1996: Guidelines for the handling of antineoplastic drugs Schweizer Archiv für Tierheilkunde 138(8): 383-386
Greco, F.A.; Hande, K.R. 1979: The clinical pharmacology and use of antineoplastic drugs Journal of the Tennessee Medical Association 72(1): 23-33
Kuduk-Jaworska, J. 1984: Platinum complexes as potential antineoplastic drugs Postepy Higieny i Medycyny Doswiadczalnej 38(3): 281-322
Gallelli, J.F.; Mahar, H. 1986: Chemical destruction and disposal of antineoplastic drugs American Journal of Hospital Pharmacy 43(7): 1679
Nissen, N.I. 1972: Evaluation of the clinical effect of antineoplastic drugs Ugeskrift for Laeger 134(25): 1345-1346